Skip To Main Content

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Atherosclerosis: Identifying risks and improving outcomes

Atherosclerosis: Identifying risks and improving outcomes

Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice

Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice

Ticagrelor vs Clopidogrel in Older Patients With ACS PCI

Ticagrelor vs Clopidogrel in Older Patients With ACS PCI

Managing the Recurrent ASCVD Risks of Your ACS Patient: A call to Action – GULF Perspective: Part 3

Managing the Recurrent ASCVD Risks of Your ACS Patient: A call to Action – GULF Perspective: Part 3

Multidisciplinary approaches in Rare Disease Patient management in KSA

Multidisciplinary approaches in Rare Disease Patient management in KSA

Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2

Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2

Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)

Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)

What are the new diagnostics modalities used to expedite Rare Disease patients identification?

What are the new diagnostics modalities used to expedite Rare Disease patients identification?

What are the new diagnostics modalities used to expedite Rare Disease patients identification?

What are the new diagnostics modalities used to expedite Rare Disease patients identification?

The Bright Study

The Bright Study

Fabry Disease from Cardiology Perspective

Fabry Disease from Cardiology Perspective

When shall we think of a rare disease from Neurological perspective

When shall we think of a rare disease from Neurological perspective